RebrandingJun 15, 2026, 08:26 AM
Sensei Biotherapeutics rebrands to Faeth, appoints new CEO & CFO
AI Summary
Sensei Biotherapeutics, Inc. announced its rebranding to Faeth Therapeutics, Inc., effective June 15, 2026, with its common stock set to trade under the new ticker "FTH" on Nasdaq from June 16, 2026. The company also appointed Anand Parikh as Chairman, President, and CEO, and Brian Stephenson as CFO, effective June 13, 2026, and strengthened its board with two new directors. This follows stockholder approval for the conversion of Series B preferred stock, which brought in approximately $200 million from a private placement, and the termination of a prior sales agreement with Jefferies LLC. The company is now focused on advancing PIKTOR, an oral therapy, with Phase 2 data expected in H2 2026.
Key Highlights
- Sensei Biotherapeutics changed its corporate name to Faeth Therapeutics, Inc., effective June 15, 2026.
- The company's common stock is expected to begin trading under the new ticker symbol "FTH" on the Nasdaq Capital Market on June 16, 2026.
- Anand Parikh was appointed Chairman, President, and Chief Executive Officer, effective June 13, 2026, with an annual base salary of $680,000 and a 60% target annual bonus.
- Brian Stephenson was appointed Chief Financial Officer and principal financial officer, effective June 13, 2026.
- The Board of Directors was strengthened with the addition of Stephen M. Hahn, M.D., and Saira Ramasastry.
- Stockholders approved the conversion of Series B preferred stock, resulting in approximately $200 million in gross proceeds from a concurrent private placement.
- The Prior Sales Agreement with Jefferies LLC, for up to $50 million in common stock sales, was terminated on June 10, 2026, with no shares sold.
- PIKTOR, an investigational all-oral multi-node inhibitor, is on track for topline Phase 2 data in advanced endometrial cancer in the second half of 2026.
Price Impact
More from SNSE